Report : Asia-Pacific ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates) 

At 3.9% CAGR, the APAC ECMO Market is speculated to be worth US$ 139.19 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the APAC ECMO market was valued at US$ 110.85 million in 2022 and is expected to reach US$ 139.19 million by 2028, registering a CAGR of 3.9% from 2022 to 2028. Growing adoption of ECMO in lung transplantation procedures and increasing survival rates with ECMO are the critical factors attributed to the APAC ECMO market expansion.         

Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge in patient undergoing lung transplantation. Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, ECMO is used penultimately in treating PGD post lung transplantation. Thus, the demand for ECMO equipment is driving APAC ECMO market.  

On the contrary, complications associated with ECMO hurdles the growth of APAC ECMO market. 

Based on modality, the APAC ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held 40.4% market share in 2022, amassing US$ 44.80 million. It is projected to garner US$ 58.43 million by 2028 to expand at 4.5% CAGR during 2022–2028.   

Based on application, the APAC ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held 55.4% market share in 2022, amassing US$ 61.44 million. It is projected to garner US$ 75.41 million by 2028 to expand at 3.5% CAGR during 2022–2028.   

Based on age group, the APAC ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held 43.3% market share in 2022, amassing US$ 48.00 million. It is projected to garner US$ 62.14 million by 2028 to expand at 4.4% CAGR during 2022–2028.   

Based on country, the APAC ECMO market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC. Our regional analysis states that China captured 29.8% market share in 2022. It was assessed at US$ 33.00 million in 2022 and is likely to hit US$ 42.59 million by 2028, exhibiting a CAGR of 4.3% during the forecast period.               

Key players dominating the APAC ECMO market are ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group among others.  

  • In May 2022, LivaNova PLC Acquired ALung Technologies, Inc. ALung Technologies, Inc., is a provider of low-flow extracorporeal carbon dioxide removal technologies for treating patients with acute respiratory failure.
  • In April 2020, Abiomed acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. With the acquisition of Cardiopulmonary Support Technology (ECMO), the company expanded its product portfolio.  

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id:

Download Free PDF Brochure